(Q33372861)

English

Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

medulloblastoma

0 references

1 reference

based on heuristic

inferred from title

1

object named as

Maryam Fouladi

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

2

object named as

Susan M Blaney

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Roger E McLendon

5

object named as

Roger McLendon

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

12

object named as

Amar Gajjar

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Tina Young Poussaint

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Burgess B Freeman

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Christine Fuller

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Adekunle M Adesina

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Michael L Hancock

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Mary K Danks

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Clinton Stewart

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

James M Boyett

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

1 November 2006

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

107

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

2291-2297

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Improving survival in recurrent medulloblastoma: earlier detection, better treatment or still an impasse?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22241

21 January 2018

Response of recurrent medulloblastoma to low-dose oral etoposide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22241

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy of recurrent medulloblastoma with combined procarbazine, CCNU, and vincristine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22241

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of treatment of children with recurrent medulloblastoma/primitive neuroectodermal tumors with lomustine, cisplatin, and vincristine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22241

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22241

7 January 2021

based on heuristic

inferred from DOI database lookup

Cisplatin in recurrent pediatric brain tumors. A POG Phase II study. A Pediatric Oncology Group Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22241

7 January 2021

based on heuristic

inferred from DOI database lookup

Cisplatin in the treatment of recurrent childhood primary brain tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22241

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of cisplatin therapy in recurrent childhood brain tumors. A report from the Childrens Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22241

7 January 2021

based on heuristic

inferred from DOI database lookup

Carboplatin and recurrent childhood brain tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22241

7 January 2021

based on heuristic

inferred from DOI database lookup

Carboplatin in childhood brain tumors. A Children's Cancer Study Group Phase II trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22241

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22241

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22241

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22241

7 January 2021

based on heuristic

inferred from DOI database lookup

Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22241

7 January 2021

based on heuristic

inferred from DOI database lookup

Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22241

7 January 2021

based on heuristic

inferred from DOI database lookup

Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22241

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22241

7 January 2021

based on heuristic

inferred from DOI database lookup

The significance of DNA cross-linking to cis-diamminedichloroplatinum(II)-induced cytotoxicity in sensitive and resistant lines of murine leukemia L1210 cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22241

7 January 2021

based on heuristic

inferred from DOI database lookup

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22241

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22241

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22241

7 January 2021

based on heuristic

inferred from DOI database lookup

Validation of a highly sensitive ICP-MS method for the determination of platinum in biofluids: application to clinical pharmacokinetic studies with oxaliplatin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22241

7 January 2021

based on heuristic

inferred from DOI database lookup

Surveillance scanning of children with medulloblastoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22241

7 January 2021

based on heuristic

inferred from DOI database lookup

Population pharmacokinetics of oxaliplatin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22241

7 January 2021

based on heuristic

inferred from DOI database lookup

Population pharmacokinetics of oxaliplatin in patients with metastatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22241

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22241

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.22241

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33372861&oldid=2199293848"